Literature DB >> 25485863

Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab.

Laura Willemsen1, Cornelia M Jol-van der Zijde2, Rick Admiraal3, Hein Putter4, Anja M Jansen-Hoogendijk1, Monique M Ostaijen-Ten Dam1, Juul T Wijnen5, Charlotte van Kesteren6, Jacqueline L M Waaijer1, Arjan C Lankester1, Robbert G M Bredius1, Maarten J D van Tol1.   

Abstract

The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is strongly affected by the kinetics of reconstitution of the immune system. This study compared the effects of antithymocyte globulin (ATG) and alemtuzumab on various outcome parameters after HSCT. The study cohort consisted of 148 children, with a median age of 9.6 years (range, .4 to 19.0), who underwent HSCT for malignant and benign hematological disorders in a single HSCT unit. Conditioning included ATG (n = 110) or alemtuzumab (n = 38). Cox proportional hazard regression analysis showed that alemtuzumab significantly delayed the recovery of CD3(+) T cells and CD4(+)as well as CD8(+) T cell subsets (P ≤ .001) and natural killer (NK) cells (P = .008) compared with ATG. In both ATG- and alemtuzumab-treated patients, shorter drug exposure lead to significantly faster recovery of T cells. Alemtuzumab was associated with lower donor chimerism 3 and 6 months after transplantation and a higher risk of disease relapse (P = .001). The overall survival and event-free survival risks were significantly lower for alemtuzumab-treated patients (P = .020 and P < .001, respectively). Patients who received alemtuzumab showed a trend to lower risk of acute graft-versus-host disease, more human adenovirus, and less Epstein-Barr virus reactivations compared with patients who received ATG. These data indicate that children treated with alemtuzumab as part of the conditioning regimen have a slower T cell and NK cell reconstitution compared with those treated with ATG, which compromises the overall and event-free survival. Prolonged length of lympholytic drug exposure delayed the T cell recovery in both ATG- and alemtuzumab-treated patients. Therefore, we recommend detailed pharmacokinetic/pharmacodynamic (PK/PD) analyses in a larger cohort of patients to develop an algorithm aiming at optimization of the serotherapy containing conditioning regimen.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alemtuzumab; Antithymocyte globulin; Children; Hematopoietic stem cell transplantation; Immune reconstitution; Survival

Mesh:

Substances:

Year:  2014        PMID: 25485863     DOI: 10.1016/j.bbmt.2014.11.674

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  22 in total

1.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

Review 2.  Reconstitution of adaptive immunity after umbilical cord blood transplantation: impact on infectious complications.

Authors:  Sophie Servais; Muriel Hannon; Régis Peffault de Latour; Gérard Socie; Yves Beguin
Journal:  Stem Cell Investig       Date:  2017-05-25

Review 3.  Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.

Authors:  Coco de Koning; Rick Admiraal; Stefan Nierkens; Jaap Jan Boelens
Journal:  Stem Cell Investig       Date:  2017-05-16

4.  Dynamical Systems Modeling of Early-Term Immune Reconstitution with Different Antithymocyte Globulin Administration Schedules in Allogeneic Stem Cell Transplantation.

Authors:  Viktoriya Zelikson; Gary Simmons; Natasha Raman; Elizabeth Krieger; Anatevka Rebiero; Kelly Hawks; May Aziz; Catherine Roberts; Alden Chesney; Jason Reed; Ronald Gress; Amir Toor
Journal:  Transplant Cell Ther       Date:  2021-10-21

5.  GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Authors:  Rohtesh S Mehta; Shernan G Holtan; Tao Wang; Michael T Hemmer; Stephen R Spellman; Mukta Arora; Daniel R Couriel; Amin M Alousi; Joseph Pidala; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Medhat Askar; Jeffery J Auletta; Vijaya Bhatt; Christopher Bredeson; Saurabh Chhabra; Shahinaz Gadalla; James Gajewski; Robert Peter Gale; Usama Gergis; Peiman Hematti; Gerhard C Hildebrandt; Yoshihiro Inamoto; Carrie Kitko; Pooja Khandelwal; Margaret L MacMillan; Navneet Majhail; David I Marks; Parinda Mehta; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Miguel Angel Diaz; Tim Prestidge; Muna Qayed; Hemalatha Rangarajan; Olle Ringden; Ayman Saad; Bipin N Savani; Sachiko Seo; Ami Shah; Niketa Shah; Kirk R Schultz; Melhem Solh; Thomas Spitzer; Jeffrey Szer; Takanori Teshima; Leo F Verdonck; Kirsten M Williams; Baldeep Wirk; John Wagner; Jean A Yared; Daniel J Weisdorf
Journal:  Blood Adv       Date:  2019-05-14

6.  Unconditioned unrelated donor bone marrow transplantation for IL7Rα- and Artemis-deficient SCID.

Authors:  C C Dvorak; K Patel; J M Puck; J Wahlstrom; M J Dorsey; R Adams; J Facchino; M J Cowan
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

7.  CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation.

Authors:  Coco de Koning; Susan Prockop; Ichelle van Roessel; Nancy Kernan; Elizabeth Klein; Jurgen Langenhorst; Celina Szanto; Mirjam Belderbos; Marc Bierings; Farid Boulad; Dorine Bresters; Maria Cancio; Kevin Curran; Wouter Kollen; Richard O'Reilly; Andromachi Scaradavou; Barbara Spitzer; Birgitta Versluijs; Alwin Huitema; Caroline Lindemans; Stefan Nierkens; Jaap Jan Boelens
Journal:  Blood       Date:  2021-02-11       Impact factor: 22.113

Review 8.  Autosomal recessive osteopetrosis: mechanisms and treatments.

Authors:  Sara Penna; Anna Villa; Valentina Capo
Journal:  Dis Model Mech       Date:  2021-05-10       Impact factor: 5.758

9.  Risk of serious bloodstream infections is low in pediatric hematopoietic stem cell transplant (HSCT) recipients with fevers due to antithymocyte globulins and alemtuzumab.

Authors:  B Horn; S O'Kane; R L Wattier; J T Wahlstrom; A Melton; M J Cowan; C C Dvorak
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.174

Review 10.  A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition.

Authors:  Markus J Barten; Uwe Schulz; Andres Beiras-Fernandez; Michael Berchtold-Herz; Udo Boeken; Jens Garbade; Stephan Hirt; Manfred Richter; Arjang Ruhpawar; Jan Dieter Schmitto; Felix Schönrath; Rene Schramm; Martin Schweiger; Markus Wilhelm; Andreas Zuckermann
Journal:  Transplant Direct       Date:  2016-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.